Generic Name and Formulations:
Fenofibrate 48mg, 145mg; tabs.
Indications for TRICOR:
Adjunct to diet in hypertriglyceridemia (Types IV and V), and to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia (Types IIa and IIb). Limitations of use: not shown to reduce coronary heart disease morbidity and mortality in a controlled trial of patients with type 2 diabetes mellitus.
Take without regard to food. Hypertriglyceridemia: 48–145mg/day, adjust at 4–8 week intervals. Hypercholesterolemia, dyslipidemia: initially 145mg/day. Renal impairment or elderly: initially 48mg/day. Discontinue if inadequate response after 2 months on max dose.
Hepatic dysfunction. Primary biliary cirrhosis. Severe renal dysfunction. Gallbladder disease.
Renal impairment. Monitor CBCs for first year; monitor liver function; discontinue if ALT (SGPT) levels >3×ULN persist. Discontinue if markedly elevated CPK levels, myopathy, gallstones, hypersensitivity reactions (acute and delayed), or severely depressed HDL-C levels occur (do not reinitiate). Pregnancy. Nursing mothers: not recommended (during and for 5 days after final dose).
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1hr before or 4–6hrs after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), colchicine, other nephrotoxic drugs.
Abnormal liver function tests, elevated CPK, rhinitis, myopathy, cholelithiasis, pancreatitis, increased serum creatinine, hypersensitivity reactions (may be severe), rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Opioids: Clinician Concern and Prescribing Practices
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- CDC: 8.8% of Individuals in the United States Uninsured in First Half of 2018
- Patient Experiences Shed Light on Diagnostic Errors
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Wikipedia in Medical Education: An Educator's Guide to Crowdsourcing